PMID- 31277692
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20211204
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 12
IP  - 1
DP  - 2019 Jul 5
TI  - Targeting mTOR for cancer therapy.
PG  - 71
LID - 10.1186/s13045-019-0754-1 [doi]
LID - 71
AB  - Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell 
      growth, survival, metabolism, and immunity. mTOR is usually assembled into 
      several complexes such as mTOR complex 1/2 (mTORC1/2). In cooperation with 
      raptor, rictor, LST8, and mSin1, key components in mTORC1 or mTORC2, mTOR 
      catalyzes the phosphorylation of multiple targets such as ribosomal protein S6 
      kinase beta-1 (S6K1), eukaryotic translation initiation factor 4E binding protein 1 
      (4E-BP1), Akt, protein kinase C (PKC), and type-I insulin-like growth factor 
      receptor (IGF-IR), thereby regulating protein synthesis, nutrients metabolism, 
      growth factor signaling, cell growth, and migration. Activation of mTOR promotes 
      tumor growth and metastasis. Many mTOR inhibitors have been developed to treat 
      cancer. While some of the mTOR inhibitors have been approved to treat human 
      cancer, more mTOR inhibitors are being evaluated in clinical trials. Here, we 
      update recent advances in exploring mTOR signaling and the development of mTOR 
      inhibitors for cancer therapy. In addition, we discuss the mechanisms underlying 
      the resistance to mTOR inhibitors in cancer cells.
FAU - Hua, Hui
AU  - Hua H
AD  - State Key Laboratory of Biotherapy, Laboratory of Stem Cell Biology, National 
      Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, 
      Chengdu, 610041, China.
FAU - Kong, Qingbin
AU  - Kong Q
AD  - Laboratory of Oncogene, Cancer Center, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Zhang, Hongying
AU  - Zhang H
AD  - Laboratory of Oncogene, Cancer Center, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Wang, Jiao
AU  - Wang J
AD  - School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
FAU - Luo, Ting
AU  - Luo T
AD  - Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Jiang, Yangfu
AU  - Jiang Y
AD  - Laboratory of Oncogene, Cancer Center, West China Hospital, Sichuan University, 
      Chengdu, China. jyangfu@scu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190705
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Molecular Targeted Therapy/methods
MH  - Neoplasms/*drug therapy/metabolism
MH  - Protein Kinase Inhibitors/pharmacology/*therapeutic use
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
PMC - PMC6612215
OTO - NOTNLM
OT  - Cancer
OT  - Drug resistance
OT  - Oncogene
OT  - Targeted therapy
OT  - mTOR
COIS- The authors declare that they have no competing interests.
EDAT- 2019/07/07 06:00
MHDA- 2020/06/17 06:00
PMCR- 2019/07/05
CRDT- 2019/07/07 06:00
PHST- 2019/04/22 00:00 [received]
PHST- 2019/06/14 00:00 [accepted]
PHST- 2019/07/07 06:00 [entrez]
PHST- 2019/07/07 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2019/07/05 00:00 [pmc-release]
AID - 10.1186/s13045-019-0754-1 [pii]
AID - 754 [pii]
AID - 10.1186/s13045-019-0754-1 [doi]
PST - epublish
SO  - J Hematol Oncol. 2019 Jul 5;12(1):71. doi: 10.1186/s13045-019-0754-1.